StockVS

Archimedes Tech SPAC Partners II Co. (ATII) Aandelenanalyse

Financiële Diensten

Archimedes Tech SPAC Partners II Co.

$11.33

$-0.05 (-0.44%)

Laatst bijgewerkt: 26 mei 2026

Koersverloop

Analyse

Bedrijfsoverzicht

Archimedes Tech SPAC Partners II Co. operates as a shell entity within the financial services sector, specifically categorized under the industry of shell companies, which implies it currently lacks significant operational assets or ongoing business activities. The company's primary objective is to execute a business combination, such as a merger, asset acquisition, or recapitalization, with one or more targets operating in the technology industry. At present, the firm does not employ any staff, as the employee count is listed as N/A, reflecting its transitional nature as a special purpose acquisition vehicle. With a market capitalization of $308.62M, the company holds a notable valuation despite having no annual revenue reported, a metric marked as N/A in available data. This market cap indicates that the company's value is driven almost exclusively by investor expectations regarding a future merger rather than current operational cash flows or historical earnings performance, positioning it as a speculative vehicle within the financial services landscape.

Financiële gezondheid

The financial performance of Archimedes Tech SPAC Partners II Co. is characterized by reported net income of $7.99M over the trailing twelve months, while revenue and EBITDA figures are unavailable or not applicable for this specific entity. The significant presence of net income without corresponding revenue highlights the unique cost structure of a shell company, where expenses are minimal and often capitalized or structured differently than operating entities, leading to a profit margin of 0.0% on the revenue line which remains N/A. The company reports zero free cash flow, a standard characteristic for SPACs that typically reinvest capital into transaction costs or await the post-merger integration period, indicating limited immediate financial flexibility for capital expenditure but preserving liquidity for a deal. Regarding margins, the gross margin is recorded at 0.0%, the operating margin at 0.0%, and the profit margin at 0.0%, figures that reflect the absence of traditional cost of goods sold and operating leverage found in mature technology businesses. The balance sheet demonstrates a highly conservative stance with total cash holdings of $1.36M and zero outstanding debt, resulting in a debt-to-equity ratio that is not applicable due to the lack of debt or equity base typical for this stage. Furthermore, the current ratio stands at an exceptionally high 10.72, signifying that the company possesses 10.72 times the current assets necessary to cover its short-term liabilities, effectively eliminating liquidity risk prior to a merger. Return on Equity is marked as N/A due to the specific accounting treatment of SPAC trust accounts, while Return on Assets is -0.4%, a negative metric that arises from the accounting method used to treat the trust funds as assets not generating traditional operational returns.

Waarderingsbeoordeling

Valuation metrics for Archimedes Tech SPAC Partners II Co. show a Trailing Twelve Months P/E Ratio of 34.77, whereas the Forward P/E is not available, a discrepancy that implies the market is pricing in future earnings based on assumptions of a successful merger rather than projected forward growth. The Price to Book ratio is reported at -45.95, a negative figure that indicates the market price is significantly below the book value per share, often seen in SPACs where the trust account balance exceeds the market price or where the accounting book value includes significant cash reserves not reflected in market sentiment. Alternative valuation metrics such as Price to Sales and EV/EBITDA are not applicable (N/A) because the company currently generates no sales and has no EBITDA, rendering these traditional multiples irrelevant until a target company is acquired. The stock has traded between a 52-week high of $10.70 and a 52-week low of $9.96, meaning the current trading price sits within this narrow range, reflecting the limited volatility typical of shell companies awaiting a deal. The Beta value is listed as N/A, which suggests that the stock's price volatility cannot be reliably measured against the broader market in isolation, as its price action is heavily influenced by SPAC-specific events rather than general market movements.

Growth & Income

Archimedes Tech SPAC Partners II Co. does not report revenue growth or earnings growth year-over-year, as both metrics are listed as N/A, reflecting the reality that the company has no historical operational data to compare against future performance. Consequently, the concept of earnings growing faster or slower than revenue is inapplicable at this stage, as the entire growth profile is contingent upon the successful identification and closing of a business combination in the technology sector. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that any available earnings are retained within the entity to bolster the trust account or fund transaction expenses rather than being distributed to shareholders. This reinvestment strategy is standard for SPACs, where capital is preserved to facilitate the merger process rather than providing income to investors. The overall growth and income profile is therefore undefined by historical percentages and instead relies entirely on the potential upside of a future merger target, offering no current income yield and no historical growth trajectory for investors to analyze.

Vergelijking met sectorgenoten

Archimedes Tech SPAC Partners II Co. (ATII) is actief in de Lege Vennootschappen-sector. Zo verhoudt het zich tot de naaste sectorgenoten op basis van marktkapitalisatie:

Bedrijf Ticker Marktkapitalisatie K/W-verhouding
Archimedes Tech SPAC Partners II Co. ATII $335.25M 37.8
Twenty One Capital, Inc. XXI $2.49B N/A
Churchill Capital Corp X CCCX $711.00M N/A
Drugs Made In America Acquisition II Corp. DMII $641.46M 77.5

De gemiddelde K/W-verhouding in de Lege Vennootschappen-sector is 82.8x. Archimedes Tech SPAC Partners II Co. wordt verhandeld tegen een K/W van 37.8.

Deze analyse is gegenereerd door AI en dient alleen ter informatie. Het vormt geen financieel advies. Gegevens kunnen vertraagd of onnauwkeurig zijn. Doe altijd je eigen onderzoek en raadpleeg een gekwalificeerde financieel adviseur voordat je beleggingsbeslissingen neemt.

Over Archimedes Tech SPAC Partners II Co.

Archimedes Tech SPAC Partners II Co. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses in the technology industry. Archimedes Tech SPAC Partners II Co. was incorporated in 2024 and is based in Claymont, Delaware.

Bedrijfsbeschrijving wordt in het Engels weergegeven.

Bezoek website →

Belangrijke Cijfers

Marktkapitalisatie
$335.25M
K/W-verhouding
37.77
52-weken hoog
$11.40
52-weken laag
$10.09
Gem. Volume
213.24K

Gegevens verstrekt door Yahoo Finance via yfinance. Dagelijks bijgewerkt.

Bedrijfsinfo

Beurs
NASDAQ
Land
United States